Figure 3.
The combination of IL10-DC and IL35-DC ameliorated in vivo inflammatory response. Mice were injected s.c. with 50 μg of OVA in Complete Freund's Adjuvant (OVA-CFA) at day 0 and divided in five different groups. At day 14, 3 × 106 OVA-pulsed DCs were injected (via i.p.) and 1 week later they were challenged with a heat-aggregated OVA (20 mg/mL) s.c. injection in the back-right footpad. Same volume of PBS (vehicle) was injected in the contralateral footpad as control. Footpad thickness was repeatedly measured with a micrometer for 56 h before blood and organ collection. (A) Schematic timeline of the experimental procedures. (B) Footpad thickness measurements of OVA-injected footpad minus PBS-injected footpads. (C) Total increase of OVA-injected footpad thickness after challenge. (D) OVA-specific IgG1 and IgG2a antibodies in the serum of mice. Cells from the (E) inguinal lymph nodes and (F) spleen were re-stimulated with OVA (100 μg/mL) in the presence of brefeldin A (10 μg/mL) overnight and T cell populations were assessed by flow cytometry. Data are representative of at least two independent experiments (n = 5 mice/group/experiment). *P < 0.05; **P < 0.005.